Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue (y 2)

This press release contains forward-looking statements that are based on Lilly's current expectations for LY2605541(novel basal insulin), but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantee that novel basal insulin will receive the necessary clinical and manufacturing regulatory approvals or that it will prove to be commercially successful. In addition, there can be no guarantee that the companies will realize the financial and commercial results anticipated from this collaboration. Other risk factors that may affect Lilly's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. The companies undertake no duty to update forward-looking statements.

*LY2605541 is an investigational agent. Its efficacy and safety have not been finally established.

REFERENCES

1. Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Weight loss and lower nocturnal hypoglycaemia with novel long-acting basal insulin LY2605541 versus insulin glargine in patients with type 2 diabetes. EASD: 48th Annual Meeting; Berlin, Germany; 2012.

2. Curtis, B, Shi, C. Novel long-acting basal insulin analogue LY2605541 significantly reduces nocturnal hypoglycaemia and fear of hypoglycaemia compared to insulin glargine in patients with type 2 diabetes mellitus. Abstract #954. Presented at the 48th European Society for the Study of Diabetes (EASD) Annual Meeting. 1-5 October 2012, Berlin, Germany.

3. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987, 10:617-621.

4. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2011.

5. International Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: August 2, 2012.

(Logo: http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...] )

(Logo: http://photos.prnewswire.com/prnh/201108... [http://photos.prnewswire.com/prnh/201108...] )

CONTACT: Tammy Hull, Communications Manager, Lilly Diabetes,hullta@lilly.com, +1-317-651-9116; or Ute E Schmidt, Boehringer IngelheimGmbH, press@boehringer-ingelheim.com, +49(6132)77-97296

Web site: http://photos.prnewswire.com/prnh/201108...